- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02269683
Robotic vs. Laparoscopic Distal Pancreatectomy for Pancreatic Cancer (DAVID)
Randomized Controlled Trial of Robotic vs. Laparoscopic Distal Pancreatectomy for Pancreatic Cancer - The DAVID-study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Surgical resection the only potentially curative therapeutic approach in patients with pancreatic cancer. Among the clinicopathologic factors that are associated with long-term survival, a complete (i.e. R0) tumor resection is of utmost significance. Numerous reports have already demonstrated detection of tumor cells at the resection margin on microscopic examination (i.e. R1 resection) is associated with poor long-term survival. However, studies using a standardized pathological work-up of operative specimen from patients with pancreatic cancer revealed that most pancreatic resections are R1 resections. Innovative surgical techniques that reduce the incidence of R1 resections may provide a promising approach to improve the outcome of patients with pancreatic cancer.
For patients requiring a distal pancreatectomy, a laparoscopic pancreatic resection is increasingly performed, as it may enhance postoperative recovery without compromising oncological safety compared to the open approach. However, laparoscopic technique does not affect the proportion of patients with complete (R0) resections. Furthermore, the inability to control major vasculature frequently results in conversion to the open approach. The vast majority of R1 margins are located at the retroperitoneal dissection surface. Due to technical limitations, the open and the laparoscopic technique may not further reduce the incidence of positive resection margins at this location.
The 3D visualization provided by the robotic approach together with improved dexterity of the surgeon are likely to enable a meticulous dissection at the posterior dissection margin. This may result in a significant reduction of patients with positive resection margins. However, to date there has been no randomized controlled trial that compared the robotic to the laparoscopic technique. As health-care interventions need to prove efficacy and safety in well-designed randomized controlled trials, the present randomized controlled trial was designed to test, if robotic distal pancreatectomy increases the incidence of patients with complete (R0) tumor resection for pancreatic cancer. Secondary endpoints include oncological parameters such as the number of harvested lymph nodes and factors of perioperative outcome such as perioperative complications (Clavien-Dindo classification), pancreatic fistula, in-hospital mortality, blood loss and conversion rates.
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Dresden, Germany, 01307
- Department of Surgery, University Hospital Dresden
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Suspected malignant disease of the pancreas scheduled for distal pancreatectomy
- Patient eligible for laparoscopic resection
- ≥ 18 years of age
- Written informed consent
Exclusion Criteria:
- Planned multi-visceral and/or vascular resection
- Evidence of distant metastases
- Expected lack of compliance
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Robot-assisted
Distal pancreatectomy via robot-assisted minimally-invasive approach
|
|
|
ACTIVE_COMPARATOR: Laparoscopic
Distal pancreatectomy via a conventional laparoscopic approach
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
R1 resection rate
Time Frame: 10 days
|
Proportion of patients with complete macroscopic resection, but microscopic residual tumour.
Pathological evaluation will be performed by experienced, board-certified pathologists using standardized protocols according to current guidelines.
Importantly, pathologists will be blinded for patients treatment group.
|
10 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Primary Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VTG-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Tumor
-
National Cancer Institute (NCI)Active, not recruitingNeuroendocrine Tumor | Functioning Pancreatic Neuroendocrine Tumor | Intermediate Grade Lung Neuroendocrine Neoplasm | Locally Advanced Pancreatic Neuroendocrine Tumor | Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm | Low Grade Lung Neuroendocrine Neoplasm | Metastatic... and other conditionsUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Pancreatic Neuroendocrine Tumor | Pancreatic Neoplasm | Stage III Pancreatic Neuroendocrine Tumor AJCC v8 | Stage IV Pancreatic Neuroendocrine Tumor AJCC v8 | Unresectable Pancreatic Neuroendocrine TumorUnited States, Canada
-
McGill University Health Centre/Research Institute...Completed
-
National Cancer Institute (NCI)CompletedLocally Advanced Pancreatic Neuroendocrine Tumor | Pancreatic Neuroendocrine Tumor G1 | Pancreatic Neuroendocrine Tumor G2 | Pancreatic Vipoma | Pancreatic Gastrinoma | Advanced Pancreatic Neuroendocrine TumorUnited States, Canada
-
Laser Tissue Welding, Inc.National Cancer Institute (NCI); CHI St. Luke's Health, TexasCompletedPancreatic Neoplasms | Pancreatic Adenocarcinoma | Pancreatic Cyst | Pancreatic Neuroendocrine Tumor | Pancreatic Polypeptide Tumor | Pancreatic Pseudocyst | Pancreatic Glucagonoma | Pancreas Injury | Pancreatic Cystadenoma | Pancreatic Tumor, Benign | Pancreas; Insulinoma | Pancreatic Teratoma | Pancreatic Vipoma and other conditionsUnited States
-
Fudan UniversityCompletedSolid Pseudopapillary Tumor of the Pancreas | Pancreatic Tumor, BenignChina
-
Roswell Park Cancer InstituteNeuroEndocrine Tumor Research Foundation (NETRF)CompletedLung Atypical Carcinoid Tumor | Metastatic Pancreatic Neuroendocrine Tumor | Lung Typical Carcinoid TumorUnited States
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)RecruitingPancreatic Neuroendocrine Tumor | Metastatic Malignant Neoplasm in the Liver | Stage I Pancreatic Neuroendocrine Tumor AJCC v8 | Stage II Pancreatic Neuroendocrine Tumor AJCC v8 | Stage III Pancreatic Neuroendocrine Tumor AJCC v8United States, Mexico, Uruguay
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.RecruitingGastrointestinal Neuroendocrine Pancreatic TumorChina
-
Wei ZhouUnknownLiver Tumor | Gastric Tumor | Pancreatic TumorChina
Clinical Trials on Robot-assisted distal pancreatectomy
-
Hebei Medical UniversityRecruiting
-
Chang Gung Memorial HospitalCompleted
-
Shizuoka Cancer CenterUnknown
-
Cantonal Hospital of St. GallenCompletedPancreatic DiseasesSwitzerland
-
Asan Medical CenterOlympusCompletedBenign Neoplasm of Body of Pancreas | Benign Neoplasm of Tail of Pancreas
-
Hospital General Universitario de AlicanteNot yet recruitingSurgery--Complications | Pancreatic Fistula | Pancreas Disease
-
Peking Union Medical College HospitalCompletedDiabetes MellitusChina
-
Fudan UniversityRecruitingPancreatic Cancer | Surgery | LaparoscopyChina
-
Seoul National University HospitalSamsung Medical Center; Seoul St. Mary's Hospital; Asan Medical Center; Seoul National... and other collaboratorsRecruitingPancreas Neoplasm Malignant ResectableKorea, Republic of